OncoMatch

OncoMatch/Clinical Trials/NCT05148767

UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer

Is NCT05148767 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Neoadjuvant chemoradiotherapy based on irinotecan for rectal cancer stage iii.

Phase 4RecruitingZhejiang Cancer HospitalNCT05148767Data as of May 2026

Treatment: Neoadjuvant chemoradiotherapy based on irinotecanTo explore whether the application of irinotecan under the guidance of UGT1A1 gene in neoadjuvant chemotherapy and radiotherapy for locally advanced rectal cancer could improve the clinical efficacy in the real world.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Biomarker criteria

Required: UGT1A1 any tested

Detection of UGT1A1*6 and *28 gene status.

Excluded: DPYD deficiency

DPD deficiency

Disease stage

Required: Stage N POSITIVE

Clinical stage T3-4 and / or Nude positive, and the treatment plan is nCRT.

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Blood counts

hemoglobin ≥ 90g/L; ANC ≥ 1.5 × 10^9/L

Kidney function

serum creatinine <1x ULN

Liver function

ALT, AST ≤ 2.5x ULN; ALP ≤ 2.5x ULN; serum total bilirubin <1.5x ULN; serum albumin ≥ 30g/L

Cardiac function

No clinically severe (active) heart disease, NYHA class II or higher CHF, severe arrhythmia requiring medication, or MI in last 12 months

Subject blood routine and biochemical indicators do not meet the following criteria: hemoglobin ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; Alanine transaminase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal; alkaline phosphatase (ALP) ≤2.5 times the normal upper limit; serum total bilirubin <1.5 times the normal upper limit; serum creatinine <1 times the normal upper limit; serum albumin ≥ 30g / L. Clinically severe (ie, active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring medication intervention, or a history of myocardial infarction in the last 12 months

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify